Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1661

Tafasitamab

Home » Antibodies » Tafasitamab

Background of Tafasitamab

CD19 is a transmembrane glycoprotein specific to B-lineage cells, with expression maintained in over 95% of B-cell malignancies. Tafasitamab, is a humanized monoclonal antibody specifically targeting the CD19 antigen, primarily used in the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It functions as an Fc-enhanced cytolytic antibody, which means it not only directly induces apoptosis in B-cells but also engages immune effector cells to enhance antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) .

Specifications

Catalog Number:
KB-1661
Antibody Name:
Tafasitamab
Isotype:
Human IgG1,kappa
FC Muations:
Target:
CD19
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Sarkozy C, Sehn LH. New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. Ann Lymphoma. 2019; 3:310.
  2. Crump M, Neelapu SS, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.